Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy: first report from iran.
BACKGROUND
Thrombotic microangiopathy (TMA) is a rare but devastating small vessels disorder that is characterized by intravascular platelet thrombi, thrombocytopenia, and various degrees of organ ischemia and anemia, which is due to erythrocyte fragmentation in microcirculation.


OBJECTIVE
The Aim of this study was to determine the von Willebrand factor-cleaving protease (ADAMTS13) activity during the acute phase of TMA. We also investigated inhibiting antibodies against ADAMTS13 in these patients.


METHODS
In a collaborative work with Mario-Negro institute of pharmacological research in Bergamo-Italy, we registered the clinical and laboratory data, collected the serum samples, and transferred the samples to the laboratories. Serum samples were taken before the start of plasmapheresis or at least 15 days after the final exchange.


RESULTS
We recruited 40 patients (14 males and 26 females) with the mean age of 46.12 ± 17.26 years. The mean activity of ADAMTS13 was 34.58% ± 21.83%. Two patients had inhibitory antibodies against ADAMTS13 with profound deficiency of ADAMTS13 activity (< 6%). Infectious diseases were the most common underlying condition, followed by systemic lupus erythematous.


CONCLUSIONS
Majority of patients had an underlying condition and had various ADAMTS13 activity. The presence of inhibiting antibodies and accompanied complete deficiency of ADAMTS13 activity is an indicator of severity.
Chronic Kidney Disease Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran.
Mohammadreza
M
Ardalan
Chronic Kidney Disease Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran.
Parisa
P
Rezaeifar
Purpura; Syndrome; Thrombotic Microangiopathy